RxDoctor Payments Data

Christopher Hardin, MD

Internal Medicine · Fayetteville, ARNPI 1811916448

Payments from drug & device makers

$310in general payments, 2019–2025

Across 21 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$77
  • AbbVie$75
  • GSK$56
  • Pfizer$31
  • Teva Pharmaceuticals USA, Inc.$31
  • Lilly USA, LLC$23
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$310100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$310 in reported general payments places this provider in the 55th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$238,205
Medicare patients
646
Services billed
9,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide217$219,310
MounjaroTirzepatide180$209,113
Humira(Cf) PenAdalimumab12$166,325
EliquisApixaban164$140,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$75,288
JardianceEmpagliflozin65$69,195
Tresiba Flextouch U-100Insulin Degludec40$17,804
MyrbetriqMirabegron27$15,291
Advair HfaFluticasone Propion/Salmeterol27$14,638
XareltoRivaroxaban19$14,509
Breo ElliptaFluticasone/Vilanterol35$13,255
Fiasp FlextouchInsulin Aspart (Niacinamide)14$8,173
Humalog Kwikpen U-100Insulin Lispro29$7,724
Lantus SolostarInsulin Glargine,hum.Rec.Anlog75$7,647
PaxlovidNirmatrelvir/Ritonavir32$7,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$23$209,113180 claims
PfizerEliquis, Paxlovid$31$147,390196 claims
GSKTrelegy Ellipta, Breo Ellipta$56$88,543140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →